(UroToday.com) Cabozantinib inhibits tyrosine kinases including MET, VEGF receptors, and TAM family of kinases (TYRO3, MER, and AXL). Furthermore, cabozantinib is a standard-of-care for the treatment of advanced RCC, in addition to promoting an immune-permissive environment that may enhance response to immune checkpoint inhibitors. In combination with immune checkpoint inhibitors, cabozantinib has shown promising activity for other tumor types including urothelial carcinoma, castration-resistant prostate cancer, lung cancer, and hepatocellular carcinoma. During the kidney cancer session at the ESMO 2020 virtual annual meeting, Dr. Monty Pal and colleagues presented the initial results of COSMIC-021, a multicenter phase 1b study, evaluating the combination of cabozantinib plus atezolizumab in various solid tumors (NCT03170960), including first-line treatment of clear cell renal cell carcinoma (RCC).